首页> 美国政府科技报告 >Cellular Plasticity and Heterogeneity of EGFR Mutant Lung Cancer.

【24h】

Cellular Plasticity and Heterogeneity of EGFR Mutant Lung Cancer.

机译：EGFR突变肺癌的细胞可塑性和异质性。

获取原文

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Politi, K.;
展开▼
作者单位

展开▼
年度 2016
页码 1-12
总页数 12
原文格式 PDF
正文语种 eng
中图分类
关键词
Lung cancer; Mutations; Drug resistance; Phenotypic changes; Targeted therapies; Mouse models; Egfr(epidermal growth factor receptor);

机译：肺癌;突变;耐药性;表型变化;靶向治疗;小鼠模型; Egfr（表皮生长因子受体）;

相似文献

外文文献
中文文献
专利

1. EGFR敏感突变的晚期非小细胞肺癌患者EGFR-TKIs原发性耐药相关基因突变分析 [J] . 王芳, 刁夏尧, 张晓, 癌症（英文版） . 2020,第009期
2. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs [J] . Choong-kun Lee, Sora Kim, Jae Seok Lee, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2017,第期

机译：下一代测序揭示了具有抗预测抗EGFR-TKIS的EGFR-突变体非小细胞肺癌中的新抗性机制和分子异质性
3. Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI [J] . Hata Akito, Katakami Nobuyuki, Yoshioka Hiroshige, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第11期

机译：EGFR-突变型非小细胞肺癌对EGFR-TKI耐药后个别患者时空T790M异质性
4. Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer. [J] . Donev IS, Wang W, Yamada T, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第8期

机译：瞬时PI3K抑制作用诱导凋亡，并克服EGFR突变型肺癌中HGF介导的对EGFR-TKIs的抗性。
5. Proteomic analyses of EGFR-interacting proteins to elucidate differences in signal transduction downstream of lung cancer-specific mutant EGFRs [C] . Udayan Guha, Todd M. Greco, Abhilash Venugopalan, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：EGFR-相互作用蛋白的蛋白质组学分析，以阐明肺癌特异性突变蛋白的信号转导差异
6. RB1 Loss Accelerates acquired Therapeutic Resistance in EGFR Mutant Lung Adenocarcinoma via Lineage Plasticity [D] . Zhang, Letian. 2021

机译：RB1损失通过谱系可塑性加速EGFR突变体肺腺癌的获得性抗性
7. Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma [O] . Emilio Bria, Sara Pilotto, Eliana Amato, 2015

机译：通过下一代测序评估分子异质性并评估吉非替尼对EGFR突变晚期肺腺癌的反应
8. Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non–Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI [O] . Hata Akito, Katakami Nobuyuki, Yoshioka Hiroshige, 2015

机译：EGFR-突变型非小细胞肺癌对EGFR-TKI耐药后个别患者的时空T790M异质性
9. Cellular Plasticity and Heterogeneity of EGFR Mutant Lung Cancer. [R] . Politi, K. 2015

机译：EGFR突变肺癌的细胞可塑性和异质性。

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号